Literature DB >> 20704875

The rapidly advancing field of biodefense benefits many other, critical public health concerns.

James C Burnett1, Rekha G Panchal, M Javad Aman, Sina Bavari.   

Abstract

UNLABELLED: Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared? ANSWER: in a very short period of time the scientific community has responded with a massive and productive effort. Driving the research advances described in this review: 1) a vastly improved understanding of the biological mechanisms and machinery used by biothreat agents; 2) state-of-the-art high-throughput screening technologies; and 3) more efficient, standardized methods and improved protocols for detecting, identifying, and diagnosing biowarfare agents. Furthermore, as with all good science, many recent biodefense research discoveries/advances have also directly facilitated our understanding and ability to treat other diseases, including antibiotic resistant bacteria and viruses (such as HIV and SARS).

Entities:  

Year:  2005        PMID: 20704875

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  2 in total

1.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.

Authors:  Ramon Andrade de Mello; Filipa Soares Pires; Dânia Sofia Marques; Júlio Oliveira; Ana Rodrigues; Marta Soares; Isabel Azevedo; Ana Peixoto; Catarina Santos; Carla Pinto; Venceslau Hespanhol; Manuel R Teixeira; Teresina Amaro; Henrique Queiroga; António Araújo
Journal:  Tumour Biol       Date:  2012-07-29

Review 2.  Biodefence research two decades on: worth the investment?

Authors:  Carrie M Long; Andrea Marzi
Journal:  Lancet Infect Dis       Date:  2021-08       Impact factor: 71.421

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.